p38mapk inhibitor cdd-111 Search Results


p38mapk small-molecule inhibitor cdd111 (p38i)  (Aclaris Therapeutics)
90
Aclaris Therapeutics p38mapk small-molecule inhibitor cdd111 (p38i)
(A) Mice were sacrificed on day 28 and bone sections from vehicle and chemotherapy treated mice were stained for phosphor-MK2 and shows activation of the <t>p38MAPK</t> pathway following chemotherapy treatment. N≥7 per group. Data are presented as mean±SEM. (B) 16-week old C57BL/6 mice were treated with 4 once-weekly doses of vehicle (Veh) or doxorubicin (Doxo; 5 mg/kg) and provided ad libitum chow compounded with CDD-111 <t>(p38i)</t> or CDD-450 (MK2Pi). (C) Mice were sacrificed on day 28 and bone resident cells were isolated from tibias and the SASP factors IGFBB4 and CXCL12 were measured by qRT-PCR. qRT-PCR data are presented as mean±SD. (D-E) Femurs were isolated from animals treated with vehicle (Veh) or doxorubicin (Doxo) +/− p38i or +/− MK2Pi and measured by μCT to ascertain bone volume (BV) to trabecular (Tb) volume (BV/TV) of the p38i treatment cohort (D). Tb BV/TV of the MK2Pi treatment cohort (E). N≥8 per group. All data are presented as mean±SEM. *p≤0.05, **p≤0.01, ***p≤0.001.
P38mapk Small Molecule Inhibitor Cdd111 (P38i), supplied by Aclaris Therapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/p38mapk+inhibitor+cdd-111/ati+450/pmc07056549-291-1-6
Average 90 stars, based on 1 article reviews
p38mapk small-molecule inhibitor cdd111 (p38i) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
p38mapk inhibitor cdd-111  (Confluence Life Sciences)
90
Confluence Life Sciences p38mapk inhibitor cdd-111
(A) Western blot analysis demonstrating that SB203580 treatment inhibits <t>p38MAPK</t> activity. As expected, SB203580 treatment significantly impacts phosphorylation of p38MAPK’s direct downstream target, Hsp27. Total Hsp27 was used as loading control.
P38mapk Inhibitor Cdd 111, supplied by Confluence Life Sciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/p38mapk+inhibitor+cdd-111/cdd+111/pmc04049323-211-3-14
Average 90 stars, based on 1 article reviews
p38mapk inhibitor cdd-111 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


(A) Mice were sacrificed on day 28 and bone sections from vehicle and chemotherapy treated mice were stained for phosphor-MK2 and shows activation of the p38MAPK pathway following chemotherapy treatment. N≥7 per group. Data are presented as mean±SEM. (B) 16-week old C57BL/6 mice were treated with 4 once-weekly doses of vehicle (Veh) or doxorubicin (Doxo; 5 mg/kg) and provided ad libitum chow compounded with CDD-111 (p38i) or CDD-450 (MK2Pi). (C) Mice were sacrificed on day 28 and bone resident cells were isolated from tibias and the SASP factors IGFBB4 and CXCL12 were measured by qRT-PCR. qRT-PCR data are presented as mean±SD. (D-E) Femurs were isolated from animals treated with vehicle (Veh) or doxorubicin (Doxo) +/− p38i or +/− MK2Pi and measured by μCT to ascertain bone volume (BV) to trabecular (Tb) volume (BV/TV) of the p38i treatment cohort (D). Tb BV/TV of the MK2Pi treatment cohort (E). N≥8 per group. All data are presented as mean±SEM. *p≤0.05, **p≤0.01, ***p≤0.001.

Journal: Cancer research

Article Title: Therapy-induced senescence drives bone loss

doi: 10.1158/0008-5472.CAN-19-2348

Figure Lengend Snippet: (A) Mice were sacrificed on day 28 and bone sections from vehicle and chemotherapy treated mice were stained for phosphor-MK2 and shows activation of the p38MAPK pathway following chemotherapy treatment. N≥7 per group. Data are presented as mean±SEM. (B) 16-week old C57BL/6 mice were treated with 4 once-weekly doses of vehicle (Veh) or doxorubicin (Doxo; 5 mg/kg) and provided ad libitum chow compounded with CDD-111 (p38i) or CDD-450 (MK2Pi). (C) Mice were sacrificed on day 28 and bone resident cells were isolated from tibias and the SASP factors IGFBB4 and CXCL12 were measured by qRT-PCR. qRT-PCR data are presented as mean±SD. (D-E) Femurs were isolated from animals treated with vehicle (Veh) or doxorubicin (Doxo) +/− p38i or +/− MK2Pi and measured by μCT to ascertain bone volume (BV) to trabecular (Tb) volume (BV/TV) of the p38i treatment cohort (D). Tb BV/TV of the MK2Pi treatment cohort (E). N≥8 per group. All data are presented as mean±SEM. *p≤0.05, **p≤0.01, ***p≤0.001.

Article Snippet: The p38MAPK small-molecule inhibitor CDD111 (p38i) (Aclaris Therapeutics, Inc.) was compounded as described previously ( 18 ).

Techniques: Staining, Activation Assay, Isolation, Quantitative RT-PCR

(A) Western blot analysis demonstrating that SB203580 treatment inhibits p38MAPK activity. As expected, SB203580 treatment significantly impacts phosphorylation of p38MAPK’s direct downstream target, Hsp27. Total Hsp27 was used as loading control.

Journal: Cancer discovery

Article Title: p38MAPK plays a crucial role in stromal mediated tumorigenesis

doi: 10.1158/2159-8290.CD-13-0743

Figure Lengend Snippet: (A) Western blot analysis demonstrating that SB203580 treatment inhibits p38MAPK activity. As expected, SB203580 treatment significantly impacts phosphorylation of p38MAPK’s direct downstream target, Hsp27. Total Hsp27 was used as loading control.

Article Snippet: We obtained a p38MAPK inhibitor (CDD-111, also referred to as SD-0006 ( 38 ), Confluence Life Sciences) and compounded it into mouse chow.

Techniques: Western Blot, Activity Assay, Phospho-proteomics, Control

(A) RNA-seq analysis was performed on young fibroblasts, senescent fibroblasts, and senescent fibroblasts treated with SB203580. RNA-seq results were analyzed to determine the number of factors upregulated in response to senescence (SASP factors) and the number of p38MAPK-dependent factors. These results were also analyzed for overlap with the expression profiles of breast cancer (BC)-associated stroma.

Journal: Cancer discovery

Article Title: p38MAPK plays a crucial role in stromal mediated tumorigenesis

doi: 10.1158/2159-8290.CD-13-0743

Figure Lengend Snippet: (A) RNA-seq analysis was performed on young fibroblasts, senescent fibroblasts, and senescent fibroblasts treated with SB203580. RNA-seq results were analyzed to determine the number of factors upregulated in response to senescence (SASP factors) and the number of p38MAPK-dependent factors. These results were also analyzed for overlap with the expression profiles of breast cancer (BC)-associated stroma.

Article Snippet: We obtained a p38MAPK inhibitor (CDD-111, also referred to as SD-0006 ( 38 ), Confluence Life Sciences) and compounded it into mouse chow.

Techniques: RNA Sequencing, Expressing